亞太藥業(002370.SZ):注射用阿昔洛韋通過仿製藥一致性評價
格隆匯4月28日丨亞太藥業(002370.SZ)發佈公吿,公司於近日收到國家藥品監督管理局核准簽發的關於注射用阿昔洛韋的《藥品補充申請批准通知書》,公司注射用阿昔洛韋通過仿製藥質量和療效一致性評價。
注射用阿昔洛韋適用於:1、單純皰疹病毒感染:用於免疫缺陷者初發和複發性粘膜皮膚感染的治療以及反覆發作病例的預防,也用於單純皰疹性腦炎治療;2、帶狀皰疹:用於免疫缺陷者嚴重帶狀皰疹病人或免疫功能正常者彌散型帶狀皰疹的治療;3、免疫缺陷者水痘的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.